protein geranylgeranyltransferase type I subunit beta pseudogene 1Genealiases: []
Q-omics provides the consensus-scored PGGT1BP1 profile across patient tissues and cancer cell-line models. PGGT1BP1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PGGT1BP1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, PGGT1BP1 RNA expression shows 10,391 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where PGGT1BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGGT1BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGGT1BP1 survival associations across molecular data types. PGGT1BP1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGGT1BP1 RNA expression–survival associations across cancer types. High PGGT1BP1 expression shows unfavorable associations in LUAD, but favorable associations in MESO, UCS, UVM, LGG and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PGGT1BP1 RNA expression.
This table summarizes PGGT1BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PGGT1BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGGT1BP1 shows lower tumor expression in KIRC, KICH, KIRP, UCEC, THCA and BRCA. The KIRC box plot shows higher PGGT1BP1 RNA expression in normal versus tumor tissue (log2 FC = −0.403, t-test p < 0.001).
This table shows molecular features associated with PGGT1BP1 in patient tissues and cancer cell lines. In patient samples, PGGT1BP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
